ReviewThe journal of liquid biopsy2025
Liquid biopsy as a potential tool for diagnosis and clinical monitoring of cutaneous and uveal melanoma.
Review in The journal of liquid biopsy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circulating tumor DNA accelerates diagnosis and treatment guidance for metastatic uveal melanoma with hepatic lesions not amenable to biopsy.Melanoma research · 2026Article
- Precision Oncology in Ocular Melanoma: Integrating Molecular and Liquid Biopsy Biomarkers.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is the most aggressive type of skin cancer, characterized by high metastatic potential and high mortality rates. Currently, diagnosis and mutational status assessment involves the excisional tissue biopsy followed by anatomopathological and immunohistochemical analyses. However, this technique is invasive and does not assess the molecular heterogeneity of the tumor. Also, it cannot be applied for the continuous monitoring of the disease. Gathering this information is essential for tumor staging, as well as for helping to select the most appropriate therapeutic approach for the patient. To overcome these limitations, liquid biopsy has arisen as an innovative diagnostic tool, which is a molecular determination technique for assessing tumor heterogeneity. Liquid biopsy is defined as the sampling of circulating biomarkers from tumor cells in various biological matrices, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating tumor RNA, extracellular vesicles (EVs), and proteins. In this review, we will discuss the potential of liquid biopsy for the clinical assessment of cutaneous and uveal melanoma, evaluating advantages and some parameters, such as efficiency and specificity. To this end, a bibliographical survey was carried out in the main search databases for scientific articles in the health area, published between March 2019 and October 2024, using the keywords "melanoma", "biomarker", and "liquid biopsy", and 56 articles were found. All these articles highlight the potential of liquid biopsy for personalized treatment of melanoma, early screening, diagnosis and prognosis, detection of relapses, monitoring of metastases, and selection of appropriated treatments. However, additional randomized controlled clinical trials comparing the use of liquid biopsy with the diagnostic gold standard are still needed to validate and evaluate the benefits of its use in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.